SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Clinical trials for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new SYSTEMIC LIGHT CHAIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for SYSTEMIC LIGHT CHAIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize a…
Matched conditions: SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: The General Hospital of Western Theater Command • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells take aim at rare Organ-Damaging disease
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called BCMA-targeted CAR-T cells in 30 adults with relapsed or refractory light chain amyloidosis, a rare disease where abnormal proteins build up in organs. The treatment uses the patient's own immune cells, modified to at…
Matched conditions: SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody therapy aims to fight rare amyloidosis
Disease control Recruiting nowThis study tests a new drug called TQB2934 for people with systemic light chain amyloidosis, a rare disease where abnormal proteins damage organs. The drug is a bispecific antibody that helps the immune system target and destroy harmful cells. The trial will enroll 70 adults who …
Matched conditions: SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New antibody therapy shows promise for rare amyloidosis
Disease control Recruiting nowThis phase 2 trial is testing a drug called CM336 in 21 people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. CM336 is a bispecific antibody that helps the immune system target and destroy the cells making these proteins. The study…
Matched conditions: SYSTEMIC LIGHT CHAIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC